Ioannis Zachos

Dr. Ioannis Zachos


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2008 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
PSPetros Sountoulides
Petros Sountoulides
IZIoannis Zachos
Ioannis Zachos
KPK Paschalidis
K Paschalidis
PSPetros Sountoulides
Petros Sountoulides
AFA Fotiadou
A Fotiadou
TPT Podimatas
T Podimatas
Congenital renal arteriovenous malformations (AVMs) are very rare benign lesions. They are more common in women and rarely manifest in elderly people. In some cases they present with massive hematuria. Contemporary treatment consists of transcatheter selective arterial embolization which leads to resolution of the hematuria whilst preserving renal parenchyma.

28 December 2013 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
IZIoannis Zachos
Ioannis Zachos
VTVasileios Tzortzis
Vasileios Tzortzis
LMLampros Mitrakas
Lampros Mitrakas
MSMichael Samarinas
Michael Samarinas
AKAnastasios Karatzas
Anastasios Karatzas
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou

21 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
KEKonstantinos Evmorfopoulos
Konstantinos Evmorfopoulos
LMLAMPROS MITRAKAS
LAMPROS MITRAKAS
AKAthanasios Karathanasis
Athanasios Karathanasis
IZIoannis Zachos
Ioannis Zachos
VTVassilios Tzortzis
Vassilios Tzortzis
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
Upper tract urothelial carcinoma (UTUC) is a rare malignancy, occurring in 5–10% of patients diagnosed with UC, and involves the renal pelvis, calyces, or ureters. UTUC can be sporadic or hereditary as a clinical manifestation of Lynch syndrome. Therapeutic management of these patients is challenging. Following risk stratification of localized disease, patients with low-grade UTUC may undergo kidney-sparing surgery or radical nephroureterectomy (RNU) and/or chemoablation with mitomycin-c instillation to reduce recurrence. In high-grade disease, RNU followed by adjuvant chemotherapy remains the standard of care. For decades, platinum-based chemotherapy has been the cornerstone of treatment for locally advanced and metastatic disease. The aim of the present review is to summarize recent advances in UTUC’s therapeutic management through the lens of its genomic and immune landscape. Accumulating knowledge on the genetic and immune aspects of UTUC tumors has increased our understanding of their underlying biology, supporting a luminal papillary, T-cell depleted contexture and enrichment in fibroblast growth factor receptor (FGFR) expression. These advances have fueled successful clinical testing of several precision-based therapeutic approaches, including immune checkpoint inhibitors (ICIs), the antibody–drug conjugates (ADCs) enfortumab vedotin and sacituzumab govitecan, and agents targeting the FGFR axis such as erdafitinib and other kinase inhibitors, allowing their entry into the therapeutic armamentarium and improving the prognosis of these patients. Not all patients respond to these precision-based targeted therapies; thus, validating and expanding the toolkit of potential biomarkers of response or resistance, including molecular subtypes, FGFR pathway gene alterations, DNA repair gene defects, tumor mutational burden (TMB), circulating tumor DNA (ctDNA), nectin-4, TROP2, and programmed death ligand-1 (PD-L1), are key to maximizing the benefit to these particular subgroups of patients.

19 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
KEKonstantinos Evmorfopoulos
Konstantinos Evmorfopoulos
KMKonstantinos Marsitopoulos
Konstantinos Marsitopoulos
RKRaphael Karachalios
Raphael Karachalios
AKAthanasios Karathanasis
Athanasios Karathanasis
KDKonstantinos Dimitropoulos
Konstantinos Dimitropoulos
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
Testicular germ cell tumors (TGCTs) are cancers with very good prognosis, even in the metastatic setting, with high curative potential mainly attributed to the introduction of cisplatin-based chemotherapy. However, approximately 15% of the patients develop platinum-refractory disease and suffer multiple relapses. Therefore, there is an unmet need for novel therapeutic agents with improved efficacy and minimal long-term side effects. Recent advances in the development of immunotherapeutic agents, particularly immune checkpoint inhibitors (ICIs), have offered an opportunity to test their activity in various tumor types, including GCTs. This review aims to analyze the immune microenvironment of these tumors and present the most recently available data from studies that have tested immunotherapeutic agents against GCTs. The majority of the available knowledge derives from case reports or small cohort studies, particularly those involving ICIs of the PD-1/PD-L1 axis alone or in combination with anti-CTLA-4 monoclonal antibodies. Other immunotherapeutic targeted approaches, including antibody-drug conjugates, antibody prodrugs, vaccines, tyrosine kinase inhibitors, chimeric antigen receptor (CAR) T-cell therapy, have biological rationales and have shown preliminary activity or are currently being tested. Growing evidence on these and other approaches will assist in broadening the currently limited treatment armamentarium against platinum-refractory TGCTs.

18 June 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
IZIoannis Zachos
Ioannis Zachos
VTVassilios Tzortzis
Vassilios Tzortzis
Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of 177Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular.

14 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
ITIoannis Tamposis
Ioannis Tamposis
MAMaria Anagnostou
Maria Anagnostou
MPMaria Papathanassiou
Maria Papathanassiou
LMLAMPROS MITRAKAS
LAMPROS MITRAKAS
VTVassilios Tzortzis
Vassilios Tzortzis
Background: Hypoxia is recognized as a key feature of cancer growth and is involved in various cellular processes, including proliferation, angiogenesis, and immune surveillance. Besides hypoxia-inducible factor 1-alpha (HIF-1α), which is the main mediator of hypoxia effects and can also be activated under normoxic conditions, little is known about its counterpart, HIF-2. This study focused on investigating the clinical and molecular landscape of HIF-2-altered urothelial carcinoma (UC). Methods: Publicly available next-generation sequencing (NGS) data from muscle-invasive UC cell lines and patient tumor samples from the MSK/TCGA 2020 cohort (n = 476) were interrogated for the level of expression (mRNA, protein) and presence of mutations, copy number variations, structural variants in the EPAS1 gene encoding HIF-2, and findings among various clinical (stage, grade, progression-free and overall survival) and molecular (tumor mutational burden, enriched gene expression) parameters were compared between altered and unaltered tumors. Results: 19% (7/37) of UC cell lines and 7% (27/380) of patients with muscle-invasive UC display high EPAS1 mRNA and protein expression or/and EPAS1 alterations. EPAS1-altered tumors are associated with higher stage, grade, and lymph node metastasis as well as with shorter PFS (14 vs. 51 months, q = 0.01) and OS (15 vs. 55 months, q = 0.01). EPAS1 mRNA expression is directly correlated with that of its target-genes, including VEGF, FLT1, KDR, DLL4, CDH5, ANGPT1 (q < 0.001). While there is a slightly higher tumor mutational burden in EPAS1-altered tumors (9.9 vs. 4.9 mut/Mb), they are enriched in and associated with genes promoting immune evasion, including ARID5B, SPINT1, AAK1, CLIC3, SORT1, SASH1, and FGFR3, respectively (q < 0.001). Conclusions: HIF-2-altered UC has an aggressive clinical and a distinct genomic and immunogenomic profile enriched in angiogenesis- and immune evasion-promoting genes.